New TB vaccine granted orphan drug status.

New TB vaccine granted orphan drug status.

Opis bibliograficzny
Główni autorzy:	Lang, T, Hill, A, Mcshane, H, Shah, R, Towse, A, Pritchard, C, Garau, M
Format:	Journal article
Język:	English
Wydane:	2005

Podobne zapisy

Towards new TB vaccines
od: Brazier, B, i wsp.
Wydane: (2020)

Market-driven, value-based, advance commitment (MVAC): accelerating the development of a pathbreaking universal drug regimen to end TB
od: Kalipso Chalkidou, i wsp.
Wydane: (2020-04-01)

TB vaccines in clinical development
od: Ginsberg, A, i wsp.
Wydane: (2016)

TB vaccines in clinical development
od: Ginsburg, A, i wsp.
Wydane: (2016)

DEVELOPING A NEW TB VACCINE: BOOSTING BCG WITH MVA85A
od: Mcshane, H
Wydane: (2008)

Need for more TB vaccine field sites.
od: Mcshane, H
Wydane: (2009)

Development of Orphan Vaccines: An Industry Perspective
od: Jean Lang, i wsp.
Wydane: (1999-12-01)

TB vaccines in clinical development
od: Ginsberg, AM, i wsp.
Wydane: (2016)

Safety and immunogenicity of boosting BCG vaccinated subjects with BCG: comparison with boosting with a new TB vaccine, MVA85A.
od: Whelan, K, i wsp.
Wydane: (2009)

Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.
od: Minassian, A, i wsp.
Wydane: (2011)

Differential cytokine levels in adults induced by a Novel candidate TB boost vaccine, MVA85A-according to previous BCG vaccination status
od: Owiafe, P, i wsp.
Wydane: (2012)

TB vaccine development: where are we and why is it so difficult?
od: Wilkie, M, i wsp.
Wydane: (2014)

Implementation status of pharmacological studies in the development of orphan drugs
od: Saki Yokoshiki, i wsp.
Wydane: (2024-01-01)

Progress and challenges in TB vaccine development
od: Voss, G, i wsp.
Wydane: (2018)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
od: Pathan, A, i wsp.
Wydane: (2012)

NOW THE SOLUTION IS HERE – SOCIAL ASSISTANCE FOR ORPHANED CHILDREN: THE EXTENDED CHILD SUPPORT GRANT
od: Sipho Sibanda, i wsp.
Wydane: (2023-04-01)

Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults
od: Pathan, A, i wsp.
Wydane: (2012)

A review of clinical models for the evaluation of human TB vaccines.
od: O'Shea, M, i wsp.
Wydane: (2016)

Advances in orphan drug development: Time to change the status and stereotype
od: Sayanta Thakur
Wydane: (2022-01-01)

Current status and trend of clinical development of orphan drugs in China
od: Ziling Xiang, i wsp.
Wydane: (2022-07-01)

Reimbursement Status and Recommendations Related to Orphan Drugs in European Countries
od: Ewa Stawowczyk, i wsp.
Wydane: (2019-11-01)

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
od: Morrell, L, i wsp.
Wydane: (2017)

Correction: Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A.
od: Kathryn T. Whelan, i wsp.
Wydane: (2011-01-01)

Orphan drugs and rare diseases /
od: Pryde, David C., editor, i wsp.
Wydane: (2014)

Donor investment choices in developing countries: a methodology and some illustrative results based on Public-Private partnerships for product development (PD PPPs)
od: Gray, A, i wsp.
Wydane: (2007)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants
od: Odutola, A, i wsp.
Wydane: (2012)

A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.
od: Odutola, A, i wsp.
Wydane: (2012)

Current Status and Prospect of Orphan Drugs for Rare Skin Diseases in China
od: ZHANG Shan, i wsp.
Wydane: (2023-04-01)

Mechanism of coordinated access to orphan drugs
od: DeRidder R, i wsp.
Wydane: (2012-11-01)

International comparison of availability for orphan drugs: focused on approved orphan drugs in South Korea
od: Eun Young Shin, i wsp.
Wydane: (2024-12-01)

Cancer drug funding decisions in Scotland: impact of new end-of-life, orphan and ultra-orphan processes
od: Liz Morrell, i wsp.
Wydane: (2017-08-01)

FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
od: Kathleen L. Miller, i wsp.
Wydane: (2020-09-01)

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data.
od: McShane, H, i wsp.
Wydane: (2014)

A review of preclinical animal models utilised for TB vaccine evaluation in the context of recent human efficacy data
od: McShane, H, i wsp.
Wydane: (2014)

Rare diseases and orphan drugs.
od: Aronson, J
Wydane: (2006)

Predictors of orphan drug approval
od: Heemstra Harald
Wydane: (2010-10-01)

Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
od: Hans-Georg Eichler, i wsp.
Wydane: (2023-01-01)

Adenylosuccinic Acid: An Orphan Drug with Untapped Potential
od: Emma Rybalka, i wsp.
Wydane: (2023-05-01)

Financing drug discovery for orphan diseases
od: Gromatzky, Austin A., i wsp.
Wydane: (2014)

Sea Grant seeks new drugs from the sea
od: W Fenical
Wydane: (1997-07-01)